capecitabine has been researched along with Genetic Predisposition in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantrell, FL; Friedman, NA; Galust, H; Hardin, J; Minns, A; Seltzer, JA | 1 |
| Chen, W; Li, M; Sun, X; Wang, Z; Wei, H; Zou, X | 1 |
| Alba, E; Benítez, J; Caronia, D; Cuadrado, A; de la Torre-Montero, JC; García-Saenz, JA; González-Neira, A; Kojic, A; López-Fernández, LA; Losada, A; Lozano, M; Martín, M; Milne, RL; Moreno, LT; Nuñez-Torres, R; Pérez-Moreno, M; Pita, G; Ribelles, N; Ruiz-Pinto, S; Shahbazi, MN | 1 |
| Cao, LJ; Dong, SQ; He, YQ; Huang, JW; Jia, WH; Li, XZ; Wang, TM; Wu, ZY; Xue, WQ; Yang, DW; Zhang, JB; Zhang, PF; Zheng, XH | 1 |
| Chay, WY; Chia, JWK; Choo, SP; Dent, RA; Koh, KX; Koo, WH; Kwok, LL; Lo, SK; Loh, M; Mok, ZY; Ng, RCH; Soong, RCT; Syn, N; Tan, S; Tham, CK; Toh, HC; Wong, NS; Yap, YS | 1 |
| Cecchin, E; Dreussi, E; Fiocco, M; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Lunenburg, CATC; Meulendijks, D; Peters, FP; Schellens, JHM; Swen, JJ; Toffoli, G | 1 |
| Chin, HM; Chung, WC; Jun, KH; Kim, YJ | 1 |
| DU, ZL; Huang, Y; Jin, J; Li, YX; Lin, DX; Qiao, Y; Ren, H; Tan, W; Yu, DK | 1 |
| Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Legdeur, MC; Meulendijks, D; Schellens, JH | 1 |
| Amstutz, U; Beijnen, JH; Cats, A; Deenen, MJ; Froehlich, TK; Gross, E; Henricks, LM; Jennings, BA; Kleibl, Z; Kleiblova, P; Koopman, M; Largiadèr, CR; Marinaki, AM; Meulendijks, D; Palles, C; Punt, CJ; Sanderson, JD; Schellens, JH; Schwab, M; Sonke, GS; Tomlinson, I; van Kuilenburg, AB; Zanger, UM | 1 |
| Chan, SH; Koo, SX; Ngeow, J | 1 |
| Dackus, GM; Linn, SC; Marchetti, S; Schellens, JH; Schouten, PC; Sonke, GS; van Tinteren, H | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T | 1 |
| Kopper, L; Tímár, J | 1 |
| Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J | 1 |
1 review(s) available for capecitabine and Genetic Predisposition
| Article | Year |
|---|---|
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gastrointestinal Diseases; Genetic Predisposition to Disease; Hematologic Diseases; Humans; Multivariate Analysis; Neoplasms; Odds Ratio; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Severity of Illness Index; Tegafur | 2015 |
5 trial(s) available for capecitabine and Genetic Predisposition
| Article | Year |
|---|---|
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Capecitabine; Chi-Square Distribution; Dihydrouracil Dehydrogenase (NADP); Double-Blind Method; Drug Administration Schedule; Female; Folic Acid; Genetic Predisposition to Disease; Genome-Wide Association Study; Hand-Foot Syndrome; Humans; Incidence; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Logistic Models; Male; Membrane Proteins; Microfilament Proteins; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pyridoxine; Risk Assessment; Risk Factors; Severity of Illness Index; Singapore; Time Factors; Treatment Outcome | 2017 |
[Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cyclin D1; Deoxycytidine; Diarrhea; Female; Fluorouracil; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Postoperative Period; Prospective Studies; Rectal Neoplasms; Risk Factors | 2013 |
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatigue; Female; Genetic Predisposition to Disease; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Carboplatin; Clinical Protocols; Compassionate Use Trials; Disease Progression; Disease-Free Survival; Drug Dosage Calculations; Female; Genetic Predisposition to Disease; Humans; Mutation; Netherlands; Phenotype; Phthalazines; Piperazines; Receptor, ErbB-2; Research Design; Time Factors; Treatment Outcome | 2016 |
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Codon; Colorectal Neoplasms; Deoxycytidine; Epidemiologic Methods; Female; Fluorouracil; Genetic Predisposition to Disease; Genotype; Glutathione S-Transferase pi; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Treatment Outcome | 2009 |
9 other study(ies) available for capecitabine and Genetic Predisposition
| Article | Year |
|---|---|
Oral Capecitabine Exposures and Use of Uridine Triacetate: A 20-Year Retrospective Analysis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Genetic Predisposition to Disease; Humans; Middle Aged; Retrospective Studies | 2023 |
Metastatic colorectal cancer and severe hypocalcemia following irinotecan administration in a patient with X-linked agammaglobulinemia: a case report.
Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Agammaglobulinemia; Asian People; ATP-Binding Cassette Transporters; B-Lymphocytes; Calcium Channels, L-Type; Capecitabine; Colorectal Neoplasms; Complement C6; Drug Monitoring; Drug Therapy; Exome Sequencing; Genetic Association Studies; Genetic Diseases, X-Linked; Genetic Predisposition to Disease; Humans; Hypocalcemia; Immunoglobulins; Irinotecan; Male; Mutation; Oxaliplatin; PAX3 Transcription Factor; Young Adult | 2019 |
Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cadherins; Capecitabine; Cell Line; Female; Genetic Predisposition to Disease; Hand-Foot Syndrome; Haplotypes; Humans; Keratinocytes; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Risk | 2021 |
Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Capecitabine; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Hand-Foot Syndrome; Humans; Hydro-Lyases; Male; Middle Aged; Polymorphism, Single Nucleotide; Thymidylate Synthase | 2021 |
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Clinical Trials as Topic; Databases, Factual; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Genetic Predisposition to Disease; Genotype; Hematologic Diseases; Humans; Inactivation, Metabolic; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Young Adult | 2018 |
Genetic polymorphisms of vascular endothelial growth factor (VEGF) associated with gastric cancer recurrence after curative resection with adjuvant chemotherapy.
Topics: Capecitabine; Case-Control Studies; Chemotherapy, Adjuvant; Endoscopy, Digestive System; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Male; Neoplasm Recurrence, Local; Oxaliplatin; Polymorphism, Single Nucleotide; Stomach Neoplasms; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Genetic Predisposition to Disease; Glutathione Transferase; Hepatic Veno-Occlusive Disease; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Sigmoid Neoplasms | 2016 |
[Validation study of KRAS mutation in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Genes, ras; Genetic Predisposition to Disease; Genetic Testing; Humans; Leucovorin; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Pathology, Molecular; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2009 |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Colorectal Neoplasms; Cytidine Deaminase; Deoxycytidine; E2F Transcription Factors; Erythema; Female; Fluorouracil; Foot Dermatoses; Genetic Association Studies; Genetic Predisposition to Disease; Hand Dermatoses; Haplotypes; Humans; Logistic Models; Male; Middle Aged; Pain; Polymorphism, Single Nucleotide; Prodrugs; Promoter Regions, Genetic; Sequence Analysis, DNA; Syndrome; Transcription, Genetic | 2011 |